Efficacy and Safety of Direct Oral Anticoagulants Approved for Cardiovascular Indications: Systematic Review and Meta-analysis

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2018 May 26

PMID 29795629

Citations 29

Authors

Raghavendra Charan P Makam

David C Hoaglin

David D McManus

Victoria Wang

Joel M Gore

Frederick A Spencer

Richeek Pradhan

Hoang Tran

Hong Yu

Robert J Goldberg

Affiliations

Soon will be listed here.

Abstract

Background: Direct oral anticoagulants (DOACs) have emerged as promising alternatives to vitamin K antagonists (VKAs) for patients with non-valvular atrial fibrillation (NVAF) or venous thromboembolism (VTE). Few meta-analyses have included all DOACs that have received FDA approval for these cardiovascular indications, and their overall comparisons against VKAs have shortcomings in data and methods. We provide an updated overall assessment of the efficacy and safety of those DOACs at dosages currently approved for NVAF or VTE, in comparison with VKAs.

Methods: We used data from Phase 3 randomized trials that compared an FDA-approved DOAC with VKA for primary prevention of stroke in patients with NVAF or for treatment of acute VTE.

Results: Among trial participants with NVAF, DOAC recipients had a lower risk of stroke or systemic embolism [Pooled Odds Ratio (OR) 0.76, 95% Confidence Interval (CI) (0.68-0.84)], any stroke (0.80, 0.73-0.88), systemic embolism (0.56, 0.34-0.93), and total mortality (0.89, 0.84-0.95). Safety outcomes also showed a lower risk of fatal, major, and intracranial bleeding but higher risk for gastrointestinal bleeding (GIB). Patients with acute VTE randomized to DOACs had comparable risk of recurrent VTE and death (OR 0.88, 95% CI 0.75-1.03), recurrent DVT (0.83, 0.66-1.05), recurrent non-fatal PE (0.97, 0.75-1.25), and total mortality (0.94, 0.79-1.12). Safety outcomes for DOACs showed a lower risk of major, fatal, and intracranial bleeding, but similar risk of GIB.

Conclusions: Patients receiving DOACs for NVAF had predominantly superior efficacy and safety. Patients who were treated with DOACs for acute VTE had non-inferior efficacy, but an overall superior safety profile.

Citing Articles

"Evaluating the efficacy and safety of direct oral anticoagulants compared to warfarin in very morbidly obese patients with non-valvular atrial fibrillation: A retrospective cohort study".

Ezaldin S, Abdelsalam M, Annie F, Chumbe J, Gharib E Heliyon. 2025; 11(1):e41596.

PMID: 39866424 PMC: 11758958. DOI: 10.1016/j.heliyon.2024.e41596.

Therapeutic Errors Associated With Antithrombotic Medications Reported to United States Poison Centers.

Cravo E, Hays H, Badeti J, Spiller H, Rine N, Zhu M Am J Hematol. 2025; 100(4):561-574.

PMID: 39822096 PMC: 11886480. DOI: 10.1002/ajh.27595.

Real-world data on direct oral anticoagulants in BCR::ABL1-negative myeloproliferative neoplasms (MPNs): a multicenter retrospective study on behalf of scientific subcommittee on MPNs for Turkish society of hematology.

Baysal M, Aksoy E, Bedir K, Ozmen D, Patir P, Demirci U J Thromb Thrombolysis. 2024; 58(2):284-298.

PMID: 39527392 DOI: 10.1007/s11239-024-03043-5.

Incidence and Impact on Quality of Life of Heavy Menstrual Bleeding in Women on Oral Anticoagulant Therapy.

Hassan N, Schapkaitz E, Rhemtula H, Ncete N Clin Appl Thromb Hemost. 2024; 30:10760296241281366.

PMID: 39211958 PMC: 11367687. DOI: 10.1177/10760296241281366.

Direct oral anticoagulants in cirrhosis: Rationale and current evidence.

Portela C, Gautier L, Zermatten M, Fraga M, Moradpour D, Calderara D JHEP Rep. 2024; 6(8):101116.

PMID: 39100819 PMC: 11296254. DOI: 10.1016/j.jhepr.2024.101116.

References

Keisu M, Andersson T . Drug-induced liver injury in humans: the case of ximelagatran. Handb Exp Pharmacol. 2009; (196):407-18. DOI: 10.1007/978-3-642-00663-0_13. View

Giugliano R, Ruff C, Braunwald E, Murphy S, Wiviott S, Halperin J . Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013; 369(22):2093-104. DOI: 10.1056/NEJMoa1310907. View

Lauffenburger J, Farley J, Gehi A, Rhoney D, Brookhart M, Fang G . Factors driving anticoagulant selection in patients with atrial fibrillation in the United States. Am J Cardiol. 2015; 115(8):1095-101. PMC: 4380530. DOI: 10.1016/j.amjcard.2015.01.539. View

Mohapatra R, Tran M, Gore J, Spencer F . A review of the oral direct thrombin inhibitor ximelagatran: not yet the end of the warfarin era. Am Heart J. 2005; 150(1):19-26. DOI: 10.1016/j.ahj.2005.02.012. View

Sardar P, Chatterjee S, Lavie C, Giri J, Ghosh J, Mukherjee D . Risk of major bleeding in different indications for new oral anticoagulants: insights from a meta-analysis of approved dosages from 50 randomized trials. Int J Cardiol. 2014; 179:279-87. DOI: 10.1016/j.ijcard.2014.11.101. View

Schulman S, Kearon C, Kakkar A, Mismetti P, Schellong S, Eriksson H . Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med. 2009; 361(24):2342-52. DOI: 10.1056/NEJMoa0906598. View

Buller H, Decousus H, Grosso M, Mercuri M, Middeldorp S, Prins M . Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med. 2013; 369(15):1406-15. DOI: 10.1056/NEJMoa1306638. View

Bouget J, Oger E . Emergency admissions for major haemorrhage associated with direct oral anticoagulants. Thromb Res. 2015; 136(6):1190-4. DOI: 10.1016/j.thromres.2015.10.036. View

Connors J . Antidote for Factor Xa Anticoagulants. N Engl J Med. 2015; 373(25):2471-2. DOI: 10.1056/NEJMe1513258. View

10.

Russmann S, Jetter A, Kullak-Ublick G . Pharmacogenetics of drug-induced liver injury. Hepatology. 2010; 52(2):748-61. DOI: 10.1002/hep.23720. View

11.

Kearon C, Akl E, Comerota A, Prandoni P, Bounameaux H, Goldhaber S . Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012; 141(2 Suppl):e419S-e496S. PMC: 3278049. DOI: 10.1378/chest.11-2301. View

12.

Russmann S, Niedrig D, Budmiger M, Schmidt C, Stieger B, Hurlimann S . Rivaroxaban postmarketing risk of liver injury. J Hepatol. 2014; 61(2):293-300. DOI: 10.1016/j.jhep.2014.03.026. View

13.

Schulman S, Kakkar A, Goldhaber S, Schellong S, Eriksson H, Mismetti P . Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis. Circulation. 2013; 129(7):764-72. DOI: 10.1161/CIRCULATIONAHA.113.004450. View

14.

Barnes G, Lucas E, Alexander G, Goldberger Z . National Trends in Ambulatory Oral Anticoagulant Use. Am J Med. 2015; 128(12):1300-5.e2. PMC: 4658248. DOI: 10.1016/j.amjmed.2015.05.044. View

15.

Holster I, Valkhoff V, Kuipers E, Tjwa E . New oral anticoagulants increase risk for gastrointestinal bleeding: a systematic review and meta-analysis. Gastroenterology. 2013; 145(1):105-112.e15. DOI: 10.1053/j.gastro.2013.02.041. View

16.

Bauersachs R, Berkowitz S, Brenner B, Buller H, Decousus H, Gallus A . Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med. 2010; 363(26):2499-510. DOI: 10.1056/NEJMoa1007903. View

17.

Connolly S, Ezekowitz M, Yusuf S, Eikelboom J, Oldgren J, Parekh A . Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009; 361(12):1139-51. DOI: 10.1056/NEJMoa0905561. View

18.

Inoue H, Uchiyama S, Atarashi H, Okumura K, Koretsune Y, Yasaka M . Post-marketing surveillance on the long-term use of dabigatran in Japanese patients with nonvalvular atrial fibrillation: Preliminary report of the J-dabigatran surveillance. J Arrhythm. 2016; 32(2):145-50. PMC: 4823571. DOI: 10.1016/j.joa.2015.11.008. View

19.

Verma A, Cairns J, Mitchell L, Macle L, Stiell I, Gladstone D . 2014 focused update of the Canadian Cardiovascular Society Guidelines for the management of atrial fibrillation. Can J Cardiol. 2014; 30(10):1114-30. DOI: 10.1016/j.cjca.2014.08.001. View

20.

Agnelli G, Buller H, Cohen A, Curto M, Gallus A, Johnson M . Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med. 2013; 369(9):799-808. DOI: 10.1056/NEJMoa1302507. View